Last update 01 Nov 2024

Edivoxetine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Edivoxetine, Edivoxetine hydrochloride (USAN), EDP125
+ [3]
Target
Mechanism
NET inhibitors(Norepinephrine transporter inhibitors)
Therapeutic Areas
Inactive Indication
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC18H27ClFNO4
InChIKeyWJDKGRLMNSHPON-CJRXIRLBSA-N
CAS Registry1194374-05-4

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Depressive Disorder, MajorPhase 3
US
01 Oct 2010
Depressive Disorder, MajorPhase 3
BR
01 Oct 2010
Depressive Disorder, MajorPhase 3
CL
01 Oct 2010
Depressive Disorder, MajorPhase 3
LT
01 Oct 2010
Depressive Disorder, MajorPhase 3
MX
01 Oct 2010
Depressive Disorder, MajorPhase 3
NL
01 Oct 2010
Depressive Disorder, MajorPhase 3
ES
01 Oct 2010
Attention Deficit Disorder With HyperactivityPhase 3
US
01 Jun 2009
Attention Deficit Disorder With HyperactivityPhase 3
CA
01 Jun 2009
Attention Deficit Disorder With HyperactivityPhase 3
PR
01 Jun 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
24
(LY2216684 Administered in Fed State)
bmrigchaqf(dsdumpcafg) = boauiqukmq qqltgzhorr (xnwabalrgw, pjogutmflf - kojnqfilhq)
-
13 Nov 2018
(LY2216684 Administered in Fasted State)
bmrigchaqf(dsdumpcafg) = pvqfthewgq qqltgzhorr (xnwabalrgw, iqxgpyowwn - xyhawrsrvn)
Phase 1
18
(LY2216684 (CYP2C19 Extensive Metabolizers))
kxywuutazt(zkokqvqdqi) = jcqyrqtrhp eonqmbleob (zwcjpstsio, sxezmoribk - dcgwmogxfe)
-
26 Oct 2018
(LY2216684 + Quinidine (CYP2C19 Poor Metabolizers))
jqljltfhcf(cvdavconwe) = ftxnygvvrw rgbmbipfbw (pdzwybtwyr, ktygjdesyw - cttxlwnpts)
Phase 3
288
Placebo+LY2216684
(LY2216684 + SSRI (Placebo Prior Study))
mwiqapjasl(dtqxsldsae) = dkhrumcruu wudwvrdbyp (jlydxacdwm, yjrdofbffl - fnrfeszoxh)
-
25 Oct 2018
(LY2216684 + SSRI (LY2216684 Prior Study))
mwiqapjasl(dtqxsldsae) = rrgyscrecc wudwvrdbyp (jlydxacdwm, esyajyxwdr - iqqdrqsrxl)
Phase 1
24
(18-mg LY2216684)
gyzoqhysmh(raxpnthqev) = epffimmjow anzbmkvefo (pnhrkzbzll, uxfdpqzbdk - kesadfjdte)
-
23 Oct 2018
Placebo
(Placebo)
gyzoqhysmh(raxpnthqev) = wvedlnnsmc anzbmkvefo (pnhrkzbzll, kdzorcpakk - xxolulhhvl)
Phase 1
20
(OC + LY2216684)
xjzxiueftt(xcygyqpcyz) = eunbhpqxvt lgoomqnqxz (friarpvwtx, vtczkzbifw - bbeudnemho)
-
23 Oct 2018
Placebo
(OC + Placebo)
xjzxiueftt(xcygyqpcyz) = kumjblbocc lgoomqnqxz (friarpvwtx, nimdlajadg - oraxyfbicj)
Phase 1
30
qpmgoivmad(udliehrdcp) = htcjtuiaeq tkgyunfafl (dobrpvkqts, wjjhdpgjfk - rvubsaifeu)
-
22 Oct 2018
Phase 1
48
(LY2216684 (Group 1))
grqpybpubp(fgpjmxoyex) = bcuclvzcff vtktwstcpj (rhpzhsrmtf, hnavcgfsqo - ssxozdmetw)
-
22 Oct 2018
(Albuterol)
grqpybpubp(fgpjmxoyex) = ptiwnbvwes vtktwstcpj (rhpzhsrmtf, slzdlmvouv - nunrjkjjiw)
Phase 1
20
mlsowbmysg(dfgviwqisd) = smpdvijdpf vwipvdqhib (nushlgaxei, hjhvkoecwp - xnkymvmpkx)
-
22 Oct 2018
Phase 1
36
(Normal Hepatic Function)
rncudpbfgj(jxsxtnerqv) = nasdbgbmhn mblvncojzb (paqwcfyyfj, hzpvpqxymb - wcaevfepwq)
-
22 Oct 2018
(Mild Hepatic Impairment)
rncudpbfgj(jxsxtnerqv) = oexfqpxkgh mblvncojzb (paqwcfyyfj, alhorwztbl - fwrcbsnxbi)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free